论文部分内容阅读
目的 评价卡维地洛（ＣＶＤ）抗实验性心律失常作用，并与β受体阻断剂普萘洛尔（ＰＲＯ） 进行比较。方法 采用氯仿致小鼠室颤（ＶＦ） ， 哇巴因、乌头碱致豚鼠、大鼠心律失常，肾上腺素致豚鼠心律失常， 以及结扎大鼠冠状动脉诱发心律失常等５ 种模型。结果 与溶媒对照组相比， ＣＶＤ１ ｍｇ·ｋｇ－１ 显著降低氯仿诱发的小鼠ＶＦ 发生率〔１８－７５ ％（３／１６） ｖｓ８１－２５％ （１３／１６），Ｐ＜ ０－０１〕，此作用与ＰＲＯ 相似。１ ｍｇ·ｋｇ－１ ＣＶＤ 和ＰＲＯ 均显著提高致室早（ＶＥ） ， 室速（ＶＴ）， ＶＦ， 心搏停止（ＣＡ） 所需哇巴因和乌头碱用量（ Ｐ＜０－０１ ｖｓ 溶剂对照组） ；ＣＶＤ 对抗哇巴因的致心律失常作用较等剂量ＰＲＯ 显著（ Ｐ＜ ０－０１ ，ＣＶＤ ｖｓ ＰＲＯ）。ＣＶＤ 剂量依赖性地显著缩短ｉｖ 肾上腺素４０ μｇ·ｋｇ－ １ 所致心律失常持续时间，有效减少结扎冠脉诱发的缺血性心律失常ＶＴ，ＶＦ，ＣＡ 的发生率并缩短ＶＴ 的持续时间。结论 ＣＶＤ 具有抗多种实验性心律失常作用，该作用在等剂量时至少与ＰＲＯ 相近，或强于ＰＲＯ。ＣＶＤ的这种作用最终将有益于接受其治疗的原发性高血压、冠心病、充血性心力衰竭患者
Objective To evaluate the antiarrhythmic effects of carvedilol (CVD) on experimental arrhythmias and compare it with propranolol (PRO), a beta blocker. Methods Five models of ventricular fibrillation (VF), ouabain, aconitine-induced guinea pigs, rat arrhythmia, epinephrine induced guinea pig arrhythmias, and arrhythmia induced by ligation of coronary arteries in rats were induced by chloroform. Results Compared with vehicle control group, CVD1 mg · kg-1 significantly reduced the incidence of VF induced by chloroform (18-75% (3/16) vs81-25% (13/16), P <0.01) , This effect is similar to PRO. 1 mg · kg-1 CVD and PRO significantly increased the amounts of ouabain and aconitine required for ventricular tachycardia (VT), ventricular tachycardia (VF), and cardiac arrest (CA) (P <0-01 vs Solvent control group). The arrhythmic effect of CVD on ouabain was significantly higher than that of the equivalent dose PRO (P <0-01, CVD vs PRO). CVD dose-dependently significantly shortened the duration of arrhythmia induced by iv epinephrine 40 μg · kg -1, effectively reducing the incidence of VT, VF, CA and shortening the duration of VT induced by coronary artery ligation. Conclusion CVD has a variety of experimental arrhythmia, the role of at least equivalent to the PRO or PRO. This effect of CVD will ultimately benefit patients who receive their treatment of essential hypertension, coronary heart disease, congestive heart failure